Supplemental Table 1 From "Malignancy Rates Through 5 Years of Follow-up in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab: Pooled Results From the VOYAGE 1 and VOYAGE 2 Trials"

Name: Supplemental Table 1 From "Malignancy Rates Through 5 Years of Follow-up in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab: Pooled Results From the VOYAGE 1 and VOYAGE 2 Trials"
Creator: Andrew Blauvelt
Published: 2023-03-29T08:05:52.773Z
Keywords: Therapy-Related Malignancy, Biologic Therapy, Psoriasis, Drug Safety

Blauvelt, Andrew; Lebwohl, Mark; Langley, Richard; Rowland, Katelyn; Yang, Ya-Wen; Chan, Daphne; Miller, Megan; You, Yin; Yu, Jenny; Thaci, Diamant; Foley, Peter; Papp, Kim

doi:10.17632/wxc6zczscf.1

Supplemental Table 1 From "Malignancy Rates Through 5 Years of Follow-up in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab: Pooled Results From the VOYAGE 1 and VOYAGE 2 Trials"

Published: 29 March 2023| Version 1 | DOI: 10.17632/wxc6zczscf.1

Contributors:

,

Description

Supplemental Table 1, "Proportion of Guselkumab-Treated Patients With NMSC by Previous use of Psoriasis Therapy," from "Malignancy Rates Through 5 Years of Follow-up in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab: Pooled Results From the VOYAGE 1 and VOYAGE 2 Trials" accepted for publication in J Am Acad Dermatol March 9, 2023.

Files

Funding

Johnson & Johnson (United States)

Supplemental Table 1 From "Malignancy Rates Through 5 Years of Follow-up in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab: Pooled Results From the VOYAGE 1 and VOYAGE 2 Trials"

Description

Files

Categories

Funding

Licence